As a potent dual receptor agonist, this compound is extensively studied for its synergistic interaction with both the GLP-1 (Glucagon-like Peptide-1) and GIP (Glucose-dependent Insulinotropic Polypeptide) receptor pathways
To verify the legitimacy of a compounding pharmacy, patients can use the FDAs BeSafeRX program, which helps identify licensed and certified pharmacies.
CJC-1295 without the Drug Affinity Complex modification is a short-acting GHRH(1-29) analogue (Modified GRF 1-29) that drives pulsatile GH release through GHRH receptors, while Ipamorelin selectively activates the ghrelin/GHS-R1a receptor without elevating cortisol or prolactin
The authors estimate that these participants were representative of more than 20 million U.S
GP and Weight Loss Service Clinical Lead Read full bio Last reviewed on 16/12/2025 Average weight loss clinical studies references
The number of units corresponding to a specific milligram dose depends entirely on the concentration of the medicationthat is, how many milligrams are dissolved in each milliliter of solution